Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2

• 来源期刊: 药学学报（英文版）
• 年，卷（期）: 2019,（5）
• 所属期刊栏目: Original articles
• 页码范围: 1008-1020
• 页数: 13页
• 语种: 英文

摘要

Renal cell carcinoma (RCC) is one of the most common malignant tumors affecting the urogenital system,accounting for 90％ of renal malignancies.Traditional chemotherapy options are often the front-line choice of regimen in the treatment of patients with RCC,but responses may be modest or limited due to resistance of the tumor to anticarcinogen.Downregulated expression of organic cation transporter OCT2 is a possible mechanism underlying oxaliplatin resistance in RCC treatment.In this study,we observed that miR-489-3p and miR-630 suppress OCT2 expression by directly binding to the OCT2 3'-UTR.Meanwhile,via 786-O-OCT2-miRNAs stable expression cell models,we found that miRNAs could repress the classic substrate 1-methyl-4-phenylpyridinium (MPP+),fluorogenic substrate N,N-dimethyl-4-(2-pyridin-4-ylethenyl) aniline (ASP+),and oxaliplatin uptake by OCT2 both in vitro and in xenografts.In 33 clinical samples,miR-489-3p and miR-630 were significantly upregulated in RCC,negatively correlating with the OCT2 expression level compared to that in adjacent normal tissues,using tissue microarray analysis and qPCR validation.The increased binding of c-Myc to the promoter of pri-miR-630,responsible for the upregulation of miR-630 in RCC,was further evidenced by chromatin immunoprecipitation and dual-luciferase reporter assay.Overall,this study indicated that miR-489-3p and miR-630 function as oncotherapy-obstructing microRNAs by directly targeting OCT2 in RCC.